What dose and schedule of Saltikva were used in the Phase 2 trial, and how was it given?

In the Phase 2 trial, participants took Saltikva by mouth at 10⁹ colony-forming units every two weeks, after a gastric-acid neutralizer and followed by 200 ml of fluid; in the FOLFIRINOX arm, three days after each chemotherapy cycle, for up to two years or until chemotherapy stopped. The timing follows preclinical colonization peaking three days after chemotherapy. The Phase 2 dose is one log below the highest Phase 1 dose (10¹⁰ CFU), which caused no dose-limiting toxicity. This describes a research protocol and is not a treatment recommendation; Saltikva is not an approved product.